Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:1962-1969
doi: 10.1161/01.CIR.0000161831.07637.63
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, Z.-G.
Right arrow Articles by Natarajan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, Z.-G.
Right arrow Articles by Natarajan, R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*LOSARTAN POTASSIUM
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Animal models of human disease
Right arrow Type 2 diabetes

(Circulation. 2005;111:1962-1969.)
© 2005 American Heart Association, Inc.


Molecular Cardiology

Upregulation of Angiotensin II Type 1 Receptor, Inflammatory Mediators, and Enzymes of Arachidonate Metabolism in Obese Zucker Rat Kidney

Reversal by Angiotensin II Type 1 Receptor Blockade

Zhong-Gao Xu, MD, PhD; Linda Lanting, BS; Nosratola D. Vaziri, MD; Zhen Li, MD; Lili Sepassi, BA; Bernardo Rodriguez-Iturbe, MD; Rama Natarajan, PhD

From Gonda Diabetes Research Center (Z.-G.X., L.L., R.N.), Beckman Research Institute of the City of Hope, Duarte, Calif; Division of Nephrology and Hypertension (N.D.V., Z.L., L.S.), University of California at Irvine, Irvine, Calif; and Servicio Nephrologia (B.R.-I.), Hospital Universitario, Universidad del Zulia Maracaibo, Venezuela.

Correspondence to Rama Natarajan, PhD, Gonda Diabetes Research Center, Beckman Research Institute of the City of Hope, 1500 E Duarte Rd, Duarte, CA 91010. E-mail rnatarajan{at}coh.org

Received November 10, 2004; revision received December 22, 2004; accepted December 28, 2004.

Background— Severe obesity can result in proteinuria and progressive glomerulosclerosis in humans and experimental animals. The associated renal disease is ameliorated by weight reduction and/or blockade of the renin-angiotensin system. Various growth factors, cytokines, and lipid mediators are implicated in the pathogenesis of renal disease. To explore the possible involvement of these mediators in obesity-induced renal disease, we examined the expression of key enzymes of arachidonate metabolism and inflammatory genes in untreated and losartan-treated obese Zucker rats, a model of obesity, insulin resistance, and renal injury.

Methods and Results— Seven-week-old male obese Zucker rats were randomized to losartan-treated (100 mg/L drinking H2O) and untreated groups, with lean Zucker rats as controls. After 4 months, RNA and protein were obtained from renal cortical tissue for relative reverse transcription–polymerase chain reaction, Western blots, and immunohistochemistry. Compared with the lean controls, obese Zucker rats showed significant glomerular matrix expansion and increased mRNA expression of the extracellular matrix protein fibronectin, inflammatory mediators interleukin-6 and monocyte chemoattractant protein-1, and 2 major enzymes of arachidonate metabolism, namely, 12/15-lipoxygenase and cyclooxygenase-2. This was associated with significant increases in p38 and extracellular signal-regulated kinase (ERK) 1/2 mitogen-activated protein kinase activities and marked upregulation of angiotensin II type 1 receptor (AT1R) mRNA and protein expression. These abnormalities and the associated glomerulopathy and proteinuria were prevented by administration of the AT1R blocker losartan.

Conclusions— These findings indicate that obesity-induced glomerulopathy is associated with upregulation of key inflammatory mediators. These events are associated with and perhaps in part due to upregulation of AT1R, as evidenced by their reversal with AT1R blocker treatment.


Key Words: obesity • angiotensin • inflammation • kidney




This article has been cited by other articles:


Home page
Evid Based Complement Alternat MedHome page
L. He, Y. Qi, X. Rong, J. Jiang, Q. Yang, J. Yamahara, M. Murray, and Y. Li
The Ayurvedic medicine Salacia oblonga attenuates diabetic renal fibrosis in rats: suppression of angiotensin II/AT1 signaling
Evid. Based Complement. Altern. Med., August 25, 2009; (2009) nep095v1.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
Z.-G. Xu, L.-N. Miao, Y.-C. Cui, Y. Jia, H. Yuan, and M. Wu
Angiotensin II type 1 receptor expression is increased via 12-lipoxygenase in high glucose-stimulated glomerular cells and type 2 diabetic glomeruli
Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1744 - 1752.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
B. Drury, L. J. Warford-Woolgar, D. J. Herchak, N. Bankovic-Calic, G. Crow, C. G. Taylor, P. Zahradka, M. R. Ogborn, and H. M. Aukema
Dietary trans-10, cis-12 Conjugated Linoleic Acid Reduces Early Glomerular Enlargement and Elevated Renal Cyclooxygenase-2 Levels in Young Obese fa/fa Zucker Rats
J. Nutr., February 1, 2009; 139(2): 285 - 290.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. H. Siddiqui, Q. Ali, and T. Hussain
Protective Role of Angiotensin II Subtype 2 Receptor in Blood Pressure Increase in Obese Zucker Rats
Hypertension, February 1, 2009; 53(2): 256 - 261.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
V. K. Madala Halagappa, S. Tiwari, S. Riazi, X. Hu, and C. M. Ecelbarger
Chronic candesartan alters expression and activity of NKCC2, NCC, and ENaC in the obese Zucker rat
Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1222 - F1231.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
Z.-G. Xu, H. Yuan, L. Lanting, S.-L. Li, M. Wang, N. Shanmugam, M. Kato, S. G. Adler, M. A. Reddy, and R. Natarajan
Products of 12/15-Lipoxygenase Upregulate the Angiotensin II Receptor
J. Am. Soc. Nephrol., March 1, 2008; 19(3): 559 - 569.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. F. Knight, J. E. Quigley, J. Yuan, S. S. Roy, A. Elmarakby, and J. D. Imig
Endothelial Dysfunction and the Development of Renal Injury in Spontaneously Hypertensive Rats Fed a High-Fat Diet
Hypertension, February 1, 2008; 51(2): 352 - 359.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Casaclang-Verzosa, B. J. Gersh, and T. S.M. Tsang
Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation.
J. Am. Coll. Cardiol., January 1, 2008; 51(1): 1 - 11.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. D. Vaziri, Y. Bai, Z. Ni, Y. Quiroz, R. Pandian, and B. Rodriguez-Iturbe
Intra-Renal Angiotensin II/AT1 Receptor, Oxidative Stress, Inflammation, and Progressive Injury in Renal Mass Reduction
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 85 - 93.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. W. Stepp, E. I. Boesen, J. C. Sullivan, J. D. Mintz, C. D. Hair, and D. M. Pollock
Obesity augments vasoconstrictor reactivity to angiotensin II in the renal circulation of the Zucker rat
Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2537 - H2542.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
Y. Ozawa and H. Kobori
Crucial role of Rho-nuclear factor-{kappa}B axis in angiotensin II-induced renal injury
Am J Physiol Renal Physiol, July 1, 2007; 293(1): F100 - F109.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
S. Riazi, O. Khan, X. Hu, and C. A. Ecelbarger
Aldosterone infusion with high-NaCl diet increases blood pressure in obese but not lean Zucker rats
Am J Physiol Renal Physiol, September 1, 2006; 291(3): F597 - F605.
[Abstract] [Full Text] [PDF]